Treatment Options in Advanced mCSPC

Insights from 2023 ESMO Annual Meeting
Avatar

ESMO 2023 Insights: "Effect of Rapid Ultra-Low Prostate-Specific Antigen Decline in TITAN Patients With mCSPC Who Received Apalutamide + ADT"

By Insights from 2023 ESMO Annual Meeting FEATURING Axel Merseburger
By Insights from 2023 ESMO Annual Meeting FEATURING Axel Merseburger
447 views
October 30, 2023
0 Comments
Login to view comments. Click here to Login
18:59
Jochen Walz

Management of Toxicities Associated With ARSi+ADT Therapy in mCSPC

12:39
Insights from 2024 ASCO® GU Annual Meeting

ASCO® GU 2024 Insights: "Prognostic Value of FDG, PSMA, and DOT…

Feat. F. Pouliot
09:59
Insights from 2024 ASCO® GU Annual Meeting

ASCO® GU 2024 Insights: "PROMPT-2 Trial - PSA Response Among Pa…

Feat. G. Brown
17:26
PROSCA & BLADDR 2023

Local Treatment of the Prostate in Synchronous mHSPC

Feat. A. Bossi
15:59
Moffitt Cancer Center

PSA Attainment & Reduction in Frontline mHSPC

Feat. J. Chadha
21:17
Manish Kohli

Time to Castrate Resistance in mCSPC Using Standard of Care Intensif…

18:42
International Urology Cancer Summit - IUCS

Theragnostics in Metastatic Prostate Cancer: Diagnosis and Treatment

Feat. G. Gnanasegaran
23:23
Fox Chase Cancer Center

New Imaging Technology in Prostate Cancer

Feat. J. Yu